Stock Research: Knight Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Knight Therapeutics

TOR:GUD CA4990531069
100
  • Value
    56
  • Growth
    88
  • Safety
    Safety
    94
  • Combined
    93
  • Sentiment
    100
  • 360° View
    360° View
    100
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Knight Therapeutics Inc. is a specialty pharmaceutical company. It operates in the pharmaceutical industry, developing, acquiring, and distributing pharmaceutical products. The company operates in Canada, Latin America, and select international markets. In the last fiscal year, the company had a market cap of $442 million, profits of $121 million, and revenue of $258 million, with 745 employees.

more

ANALYSIS: With an Obermatt 360° View of 100 (better than 100% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Knight Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for Knight Therapeutics. The consolidated Value Rank has an attractive rank of 55, which means that the share price of Knight Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 55% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 90, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 94. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 91. ...read more

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
56 41 39 45
Growth
88 29 41 15
Safety
Safety
94 89 91 68
Sentiment
100 86 87 50
360° View
360° View
100 74 80 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
52 75 49 69
Opinions Change
96 50 50 50
Pro Holdings
n/a 55 73 16
Market Pulse
100 85 93 64
Sentiment
100 86 87 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
56 41 39 45
Growth
88 29 41 15
Safety Safety
94 89 91 68
Combined
93 55 64 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
92 59 60 64
Price vs. Earnings (P/E)
1 7 5 4
Price vs. Book (P/B)
74 80 79 85
Dividend Yield
1 1 1 1
Value
56 41 39 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
69 15 18 45
Profit Growth
71 80 93 25
Capital Growth
96 24 29 1
Stock Returns
49 51 57 71
Growth
88 29 41 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
53 75 78 79
Refinancing
98 82 77 55
Liquidity
66 41 43 25
Safety Safety
94 89 91 68

Similar Stocks

Discover high‑ranked alternatives to Knight Therapeutics and broaden your portfolio horizons.

Nutrien

TOR:NTR
Country: Canada
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Jamieson Wellness

TOR:JWEL
Country: Canada
Industry: Personal Products
Size: Medium
Full Stock Analysis

Parex Resources

TOR:PXT
Country: Canada
Industry: Oil & Gas Production
Size: Medium
Full Stock Analysis

Suncor

TOR:SU
Country: Canada
Industry: Oil & Gas Integrated
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: